Argenx posts 90% sales surge to $4.2B and first profitable year
Argenx generated $1.3 billion in Q4 and $4.2 billion in 2025 product sales, up 90% year-over-year, and delivered $1.1 billion operating income, its first profitable year. The company achieved positive Phase 3 ADAPT OCULUS results for ocular MG and awaits a May 10, 2026 PDUFA decision for seronegative gMG label expansion.
1. Strong 2025 Financial Performance
argenx reported $4.2 billion in product net sales for 2025, up 90% year-over-year, including $1.3 billion in the fourth quarter. The company achieved $1.1 billion in operating income, its first annual operating profit, driven by strong VYVGART adoption in gMG and CIDP.
2. Label Expansion and Regulatory Milestones
VYVGART achieved positive Phase 3 ADAPT OCULUS results for ocular myasthenia gravis, meeting its primary endpoint with p=0.012 and no new safety concerns. The FDA set a PDUFA target action date of May 10, 2026 for its anti-AChR antibody-negative gMG expansion, supporting broader label growth.
3. Pipeline Development and Vision 2030
argenx advances its Vision 2030 strategy with planned topline readouts in ITP, rheumatology, autoimmune myopathies and Sjogren’s through 2027. Next-generation FcRn candidates ARGX-213 and ARGX-124 enter studies in 2026 while empasiprubart and adimanebart progress toward Phase 3, underpinning future growth.